Cement industry at a cyclical low

By Mahesh Patil

The cement industry is navigating through a cyclical bottom, with expectations of a modest recovery in the second half of FY25. After a robust growth from FY22 to FY24, the demand is certainly moderating. Historically, India’s cement consumption has mirrored the GDP growth at around 6%. However, the industry saw a demand CAGR of approximately 9% over the past three years, driven by strong activity in key sectors: Rural housing (37%), urban housing (30%), infrastructure (24%) and industrial & commercial (9%).

Based on the first half results for FY25, the industry is expected to report a low single-digit volume growth this year. The second quarter has been particularly weak, with an anticipated negative volume growth. This slowdown can be attributed to a combination of factors, including reduced spending by both the state and central governments following elections, completion of major infrastructure projects and heavy rains disrupting construction activities.

However, rural demand is expected to recover in the first half of calendar year 2025, spurred by catch-up in construction after monsoon. Government spending is also expected to rebound in H2FY25, providing some relief.

Also ReadConsumers might pay more for CNG in coming months as city gas cos see cost increase by Rs 2-3/kg on lower APM allocation

In terms of capacity growth, the industry is expected to expand at an 8% CAGR from FY24 to FY27, outpacing the long-term demand growth of 6%. Approximately, 70% of this new capacity will come from the top four players. However, without a meaningful recovery in demand, industry-wide capacity utilisation —currently at around 68% — is likely to decline further.

Consolidation in the industry is accelerating, particularly in the wake of recent mergers and acquisitions. The top four players’ share of capacity is projected to rise from 50% to 55-60% over the next three years.

Margins are currently at a decadal low, but a modest recovery is anticipated. Cement prices have been declining for almost a year, with a slight uptick in recent months. While the industry has attempted multiple price hikes, only minor increases of 1-2% have been realised due to weak demand. Blended EBITDA per tonne for key players remains near decade lows, but there is hope for some margin relief as fuel prices decrease and volumes improve. 

However,

 » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth